Cosmo Pharmaceuticals
Updates & Highlights
geneonline.com · about 1 month ago
Cosmo Pharmaceuticals Completes Phase II Enrollment for Distal Ulcerative Colitis Treatment Program
TradingView · about 2 months ago
Number of shareholders of Cosmo Pharmaceuticals NV – FWB:C43
simplywall.st · 2 months ago
Cosmo Pharmaceuticals (SWX:COPN) Valuation Reassessed After Strong Phase III Alopecia Results And Regulatory Plans
Recent Openings
View all 1 jobs arrow_forwardAll Jobs
Culture & Mission
Benefits & Perks
Equity/Stock Options
Ownership in the company
Health Insurance
Medical, dental & vision
Learning Budget
Professional development
Competitive Salary
Market-rate compensation
Remote Work
Work from anywhere flexibility
Generous PTO
Paid time off
Tech Stack
Core Values
Innovation
Pushing boundaries in AI/ML technology
Collaboration
Working together to achieve more
Excellence
Striving for the highest quality
Impact
Making a difference in the world
Office Locations
Team
Are you on the team at Cosmo Pharmaceuticals?
Claim this company page to verify ownership, edit details, and respond to applicants.
Claim this company arrow_forwardNews & Press
20 recentCosmo Pharmaceuticals Completes Phase II Enrollment for Distal Ulcerative Colitis Treatment Program
Cosmo Pharmaceuticals Completes Phase II Enrollment for Distal Ulcerative Colitis Treatment Program
geneonline.com · about 1 month ago
Number of shareholders of Cosmo Pharmaceuticals NV – FWB:C43
Number of shareholders of Cosmo Pharmaceuticals NV – FWB:C43
TradingView · about 2 months ago
Cosmo Pharmaceuticals (SWX:COPN) Valuation Reassessed After Strong Phase III Alopecia Results And Regulatory Plans
Cosmo Pharmaceuticals (SWX:COPN) Valuation Reassessed After Strong Phase III Alopecia Results And Regulatory Plans
simplywall.st · 2 months ago
Cosmo Pharmaceuticals Reports Positive 12-Month Safety Data for Clascoterone 5% in Male AGA
Cosmo Pharmaceuticals Reports Positive 12-Month Safety Data for Clascoterone 5% in Male AGA
Dermatology Times · 2 months ago
Does Cosmo Pharmaceuticals' (SWX:COPN) New €2.10 Dividend Clarify Its Capital Allocation Priorities?
Does Cosmo Pharmaceuticals' (SWX:COPN) New €2.10 Dividend Clarify Its Capital Allocation Priorities?
simplywall.st · 2 months ago
Cosmo Pharmaceuticals (CMOPF) Stock Price, News & Analysis
Cosmo Pharmaceuticals (CMOPF) Stock Price, News & Analysis
MarketBeat · 3 months ago
Is It Time To Reassess Cosmo Pharmaceuticals (SWX:COPN) After The Recent Share Price Pullback
Is It Time To Reassess Cosmo Pharmaceuticals (SWX:COPN) After The Recent Share Price Pullback
simplywall.st · 3 months ago
Is It Too Late To Consider Cosmo Pharmaceuticals (SWX:COPN) After A 75% One Year Surge?
Is It Too Late To Consider Cosmo Pharmaceuticals (SWX:COPN) After A 75% One Year Surge?
Yahoo Finance · 3 months ago
Cosmo Pharmaceuticals N.V. 2025 Q4 - Results - Earnings Call Presentation (OTCMKTS:CMOPF) 2026-03-10
Cosmo Pharmaceuticals N.V. 2025 Q4 - Results - Earnings Call Presentation (OTCMKTS:CMOPF) 2026-03-10
Seeking Alpha · 4 months ago
Cosmo Pharmaceuticals (SWX:COPN) Swings To Loss And Tests Bullish Profitability Narratives
Cosmo Pharmaceuticals (SWX:COPN) Swings To Loss And Tests Bullish Profitability Narratives
simplywall.st · 4 months ago
Cosmo Pharmaceuticals Achieves 104.2M Revenue and 9.5M EBITDA in 2025; Proposes 2.10 Dividend; Establishes 2026 Growth Framework
Cosmo Pharmaceuticals Achieves 104.2M Revenue and 9.5M EBITDA in 2025; Proposes 2.10 Dividend; Establishes 2026 Growth Framework
TMX Newsfile · 4 months ago
Cosmo Pharmaceuticals Achieves 104.2M Revenue and 9.5M EBITDA in 2025; Proposes 2.10 Dividend; Establishes 2026 Growth Framework
Cosmo Pharmaceuticals Achieves 104.2M Revenue and 9.5M EBITDA in 2025; Proposes 2.10 Dividend; Establishes 2026 Growth Framework
TradingView · 4 months ago
Cosmo Pharmaceuticals' 2025 recurring revenue rises, proposes dividend
Cosmo Pharmaceuticals' 2025 recurring revenue rises, proposes dividend
TradingView · 4 months ago
Assessing Cosmo Pharmaceuticals (SWX:COPN) Valuation After Strong Multi Year Returns And Recent Share Price Pullback
Assessing Cosmo Pharmaceuticals (SWX:COPN) Valuation After Strong Multi Year Returns And Recent Share Price Pullback
Yahoo Finance · 4 months ago
Cosmo Pharmaceuticals execs head to London, Miami, Paris for investor talks
Cosmo Pharmaceuticals execs head to London, Miami, Paris for investor talks
Stock Titan · 4 months ago
Cosmo Pharmaceuticals Announces Private Placement of Treasury Shares
Cosmo Pharmaceuticals Announces Private Placement of Treasury Shares
TMX Newsfile · 5 months ago
Are Robust Financials Driving The Recent Rally In Cosmo Pharmaceuticals N.V.'s (VTX:COPN) Stock?
Are Robust Financials Driving The Recent Rally In Cosmo Pharmaceuticals N.V.'s (VTX:COPN) Stock?
Yahoo Finance · 6 months ago
Cosmo Pharmaceuticals Shares Surge After Male Hair Loss Treatment Delivers Breakthrough Phase III Results
Cosmo Pharmaceuticals Shares Surge After Male Hair Loss Treatment Delivers Breakthrough Phase III Results
Global Cosmetics News · 7 months ago
Cosmo Pharmaceuticals (SWX:COPN) Is Up 46.9% After Expanding Its Clascoterone Dermatology Franchise
Cosmo Pharmaceuticals (SWX:COPN) Is Up 46.9% After Expanding Its Clascoterone Dermatology Franchise
Yahoo Finance · 7 months ago
Cosmo Pharmaceuticals N.V.'s (VTX:COPN) biggest owners are private companies who got richer after stock soared 5.6% last week
Cosmo Pharmaceuticals N.V.'s (VTX:COPN) biggest owners are private companies who got richer after stock soared 5.6% last week
Yahoo Finance · 9 months ago